1. Home
  2. AYTU vs IVP Comparison

AYTU vs IVP Comparison

Compare AYTU & IVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • IVP
  • Stock Information
  • Founded
  • AYTU N/A
  • IVP 2020
  • Country
  • AYTU United States
  • IVP United States
  • Employees
  • AYTU N/A
  • IVP N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • IVP Diversified Commercial Services
  • Sector
  • AYTU Health Care
  • IVP Miscellaneous
  • Exchange
  • AYTU Nasdaq
  • IVP Nasdaq
  • Market Cap
  • AYTU 8.3M
  • IVP 7.8M
  • IPO Year
  • AYTU N/A
  • IVP 2023
  • Fundamental
  • Price
  • AYTU $1.78
  • IVP $1.82
  • Analyst Decision
  • AYTU
  • IVP
  • Analyst Count
  • AYTU 0
  • IVP 0
  • Target Price
  • AYTU N/A
  • IVP N/A
  • AVG Volume (30 Days)
  • AYTU 3.7M
  • IVP 75.0K
  • Earning Date
  • AYTU 05-14-2025
  • IVP 05-15-2025
  • Dividend Yield
  • AYTU N/A
  • IVP N/A
  • EPS Growth
  • AYTU N/A
  • IVP N/A
  • EPS
  • AYTU N/A
  • IVP N/A
  • Revenue
  • AYTU $77,691,000.00
  • IVP $15,399,751.00
  • Revenue This Year
  • AYTU N/A
  • IVP N/A
  • Revenue Next Year
  • AYTU $8.14
  • IVP N/A
  • P/E Ratio
  • AYTU $6.70
  • IVP N/A
  • Revenue Growth
  • AYTU N/A
  • IVP N/A
  • 52 Week Low
  • AYTU $0.95
  • IVP $1.26
  • 52 Week High
  • AYTU $3.23
  • IVP $401.50
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 55.38
  • IVP 61.84
  • Support Level
  • AYTU $1.90
  • IVP $1.43
  • Resistance Level
  • AYTU $2.70
  • IVP $1.77
  • Average True Range (ATR)
  • AYTU 0.20
  • IVP 0.21
  • MACD
  • AYTU -0.01
  • IVP 0.01
  • Stochastic Oscillator
  • AYTU 37.84
  • IVP 63.85

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About IVP Inspire Veterinary Partners Inc.

Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.

Share on Social Networks: